ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)

Merck Sharp & Dohme LLC1,505,647 enrolled

Overview

This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.

Study Type

OBSERVATIONAL

Enrollment

1,505,647

Conditions

Herpes Zoster Shingles

Interventions

ZOSTAVAX™BIOLOGICAL

ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use

Eligibility

Sex: ALLMin age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Participants with continuous Kaiser Permanente Northern California (KPNC) membership since becoming age-eligible for ZOSTAVAX™ and with 12 months of continuous enrollment in KPNC before their study start date Exclusion Criteria:

Outcomes

Primary Outcomes

Incidence of Herpes Zoster in Vaccinated and Unvaccinated Cohorts, Overall, and by Age (50-59, 60-69, 70-79 ≥80) at Vaccination

Time frame: 10 years

Incidence of Herpes Zoster in Vaccinated and Unvaccinated Cohorts by Time since Vaccination

Time frame: 10 years

Secondary Outcomes

Incidence of Postherpetic Neuralgia in Vaccinated and Unvaccinated Cohorts, Overall, and by Age (50-59, 60-69, 70-79, ≥80) at Vaccination

Time frame: 10 years

Incidence of Postherpetic Neuralgia in Vaccinated and Unvaccinated Cohorts by Time since Vaccination

Time frame: 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.